Jan 28, 2021
Lipocine Closes Underwritten Public Offering Of Common Stock
Jan 26, 2021
Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock
Jan 25, 2021
Lipocine Announces Launch Of Public Offering Of Common Stock
Jan 14, 2021
Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
Jan 12, 2021
Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects
Jan 04, 2021
Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference
Dec 30, 2020
Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study
Dec 29, 2020
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics
Dec 08, 2020
Lipocine Announces Deletion of Unauthorized Changes to Company's Website
Dec 04, 2020
Lipocine Provides New Regulatory Update on TLANDO(TM)
Nov 10, 2020
Lipocine Announces Third Quarter 2020 Financial and Operational Results
Nov 05, 2020
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience(TM)
Sep 21, 2020
Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study
Aug 28, 2020
Lipocine Provides Regulatory Update for TLANDO(TM)
Aug 06, 2020
Lipocine Announces Second Quarter 2020 Financial and Operational Results
Aug 03, 2020
Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results
Jul 31, 2020
Lipocine Announces Derivative Suit Was Dismissed
Jul 13, 2020
Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement
May 15, 2020
Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020
May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model